JP2000139451A - Promoter for growth of enteric butyric acid bacterium - Google Patents
Promoter for growth of enteric butyric acid bacteriumInfo
- Publication number
- JP2000139451A JP2000139451A JP10312980A JP31298098A JP2000139451A JP 2000139451 A JP2000139451 A JP 2000139451A JP 10312980 A JP10312980 A JP 10312980A JP 31298098 A JP31298098 A JP 31298098A JP 2000139451 A JP2000139451 A JP 2000139451A
- Authority
- JP
- Japan
- Prior art keywords
- butyric acid
- palatinose
- bacteria
- growth
- turanose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、ヒトの腸内の酪酸
菌に高選択的に利用されてその生育、増殖を促進する腸
内酪酸菌生育促進剤に関する。The present invention relates to an intestinal butyric acid bacterium growth promoter which is highly selectively used for butyric acid bacterium in human intestine to promote its growth and proliferation.
【０００２】[0002]
【従来の技術】腸内菌であるクロストリジウム・ブチリ
カム（Clostridium butyricum）に属する酪酸菌は、食
中毒病原菌に対して高い生育阻害活性を有すること（Ja
pan. J. Pharmacol., 50, 495-498(1989)等）や急性及
び慢性の消化器疾患に対しても有効であることが臨床試
験により明らかにされている（新薬と臨床25, 1505-150
9(1976)等）。さらに日和見菌であるクロストリジウム
・ディフィシル（Clostridium difficile）の増加によ
って発症する下痢症に対して酪酸菌が有効であることが
報告されている（小児科臨床41, 2409-2414(1988)
等）。このように腸内酪酸菌は、消化器疾患に対して有
用な働きをする有用菌種であるが、その他酪酸生成によ
る腸内pHの低下、腸管上皮細胞の活性化及び修復、大腸
における水分吸収の促進、有害菌の増殖抑制や腸内腐敗
物質の生成抑制といった効果が知られている。BACKGROUND OF THE INVENTION Butyric acid bacteria belonging to the intestinal bacterium Clostridium butyricum have high growth inhibitory activity against food poisoning pathogens (Ja).
Pan. J. Pharmacol., 50, 495-498 (1989)) and acute and chronic gastrointestinal diseases have been shown to be effective in clinical studies (new drugs and clinical 25, 1505- 150
9 (1976)). Furthermore, butyric acid bacteria have been reported to be effective against diarrhea caused by an increase in the opportunistic bacterium Clostridium difficile (Pediatric Clinic 41, 2409-2414 (1988)).
etc). As described above, intestinal butyric acid bacteria are useful bacterial species that play a useful role in digestive diseases, but also reduce intestinal pH due to butyric acid production, activate and repair intestinal epithelial cells, and absorb water in the large intestine. Effects are known, such as promotion of bacterial growth, suppression of harmful bacteria growth, and suppression of intestinal putrefactive substances.
【０００３】[0003]
【発明が解決しようとする課題】しかしこうした有用菌
種である酪酸菌の増殖に必要な因子、すなわち酪酸菌に
高選択的に資化され、酪酸を効率よく生成させる物質は
ほとんど知られていなかった。However, little is known about the factors necessary for the growth of butyric acid bacteria, which are useful bacterial species, that is, substances that can be efficiently utilized by butyric acid bacteria and produce butyric acid efficiently. Was.
【０００４】[0004]
【課題を解決するための手段】本発明者らは、ツラノー
ス、パラチノースまたはその類縁体が、腸内の有害菌に
利用されず、腸内の酪酸菌に高選択的に資化されて酪酸
菌の生育を促進し、酪酸生成量を増加させ得ることを見
出した。DISCLOSURE OF THE INVENTION The present inventors have found that turanose, palatinose or analogs thereof are not utilized as harmful bacteria in the intestine, but are highly selectively assimilated by butyric acid bacteria in the intestine, and It has been found that the growth of butyric acid can be promoted and the production of butyric acid can be increased.
【０００５】すなわち本発明は、ツラノース、パラチノ
ースまたはパラチノース類縁体を有効成分とする腸内酪
酸菌生育促進剤を提供するものである。[0005] That is, the present invention provides an intestinal butyric acid bacteria growth promoter comprising turanose, palatinose or a palatinose analog as an active ingredient.
【０００６】[0006]
【発明の実施の形態】一般にグルコースはビフィズス菌
（Bifidobacteriaceae）や酪酸菌等の腸内有用菌のみな
らず、クロストリジウム パーフリンゲンス（Cl. perf
ringens）等の腸内有害菌やバクテロイデス ブルガタ
ス（Bacteroides vulgatus）等の日和見菌にも資化され
る。またジフルクトース無水物、キシラン等の糖類は、
有害菌、日和見菌に資化されないが、酪酸菌等の有用菌
にも資化されない。本発明に用いるツラノース、パラチ
ノースまたはパラチノース類縁体は、腸内有害菌や日和
見菌等にほとんど資化されず、酪酸菌のみが資化して酪
酸生成を促進するものであり、かかる性質を有する糖類
はほとんど知られていなかった。DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS In general, glucose is used not only for intestinal useful bacteria such as Bifidobacteriaceae and butyric acid bacteria, but also for Clostridium perfringens (Cl. Perf.).
Intestinal harmful bacteria such as ringens) and opportunistic bacteria such as Bacteroides vulgatus are also utilized. Saccharides such as difructose anhydride and xylan are:
It is not assimilated by harmful bacteria or opportunistic bacteria, but is not assimilated by useful bacteria such as butyric acid bacteria. Turanose, palatinose or palatinose analogs used in the present invention are hardly assimilated to intestinal harmful bacteria or opportunistic bacteria, etc., but are only assimilated by butyric acid bacteria to promote butyric acid production. Little was known.
【０００７】ツラノース、パラチノースは、無水物、水
和物のいずれでもよいが、パラチノースは１水和物が好
ましい。パラチノース類縁体としては、例えばパラチノ
ースの水素添加体（還元体）であるパラチニット、及び
その最小構造単位である１−Ｏ−α−Ｄ−グルコピラノ
シル−Ｄ−マンニトール等のマンニトール誘導体、６−
Ｏ−α−Ｄ−グルコピラノシル−Ｄ−グルシトール等の
グルシトール誘導体等が挙げられる。これらは市販品を
用い得る。本発明においてはこれらを１種以上用い得
る。ツラノース、パラチノース及びパラチノース類縁体
は、液状、粉末状いずれの形態でも用い得る。[0007] Turanose and palatinose may be either anhydrous or hydrated, but palatinose is preferably monohydrate. Examples of palatinose analogs include palatinit, which is a hydrogenated product (reduced product) of palatinose, and mannitol derivatives such as 1-O-α-D-glucopyranosyl-D-mannitol, which is the minimum structural unit thereof,
Glucitol derivatives such as O-α-D-glucopyranosyl-D-glucitol and the like can be mentioned. These can use a commercial item. In the present invention, one or more of these may be used. Turanose, palatinose and palatinose analogs can be used in any form of liquid or powder.
【０００８】本発明の腸内酪酸菌生育促進剤は、ツラノ
ース、パラチノース及びパラチノース類縁体をそのまま
用いてもよいが、これらの必須糖類以外に、トウモロコ
シ澱粉食物繊維等の食物繊維、セロビオース等のオリゴ
糖、ビタミン類、ミネラル類等を配合すると、腸内酪酸
菌の生育がさらに促進されるため好ましい。As the intestinal butyric acid bacteria growth promoter of the present invention, turanose, palatinose and palatinose analogs may be used as they are, but in addition to these essential sugars, dietary fibers such as corn starch dietary fiber and oligos such as cellobiose. It is preferable to add sugars, vitamins, minerals, etc., because the growth of intestinal butyric bacteria is further promoted.
【０００９】本発明の腸内酪酸菌生育促進剤は、任意の
腸内酪酸菌の生育を促進し得るが、特にクロストリジウ
ム ブチリカムに対する生育促進が特に著しい。The intestinal butyric acid bacteria growth promoter of the present invention can promote the growth of any intestinal butyric acid bacteria, but is particularly remarkable in the growth of Clostridium butyricum.
【００１０】本発明の腸内酪酸菌生育促進剤は、医薬品
または飲食物とすることが好ましい。医薬品とする場合
には、上記必須糖類の他に、必要に応じて上記食物繊維
等、香料、着色料、矯味剤、安定化剤、保存剤、滑沢
剤、賦形剤、結合剤、崩壊剤等を適宜配合し、常法に従
って例えば糖衣剤等の形態に製造できる。また飲食物と
する場合には、上記必須糖類の他に、必要に応じて上記
食物繊維等、香料、着色料、矯味剤等を適宜配合し、例
えば菓子、清涼飲料等の形態に製造できる。The intestinal butyric acid bacterium growth promoter of the present invention is preferably used as a drug or food or drink. In the case of pharmaceuticals, in addition to the above essential sugars, if necessary, the above-mentioned dietary fibers, flavors, coloring agents, flavoring agents, stabilizers, preservatives, lubricants, excipients, binders, disintegration And the like can be appropriately compounded and produced in the form of, for example, a sugar coating according to a conventional method. In the case of foods and drinks, in addition to the above essential sugars, the above-mentioned dietary fiber and the like, flavors, coloring agents, flavoring agents, and the like may be appropriately blended, if necessary, to produce, for example, confectionery and soft drinks.
【００１１】本発明の腸内酪酸菌生育促進剤中の、ツラ
ノース、パラチノースまたはパラチノース類縁体の配合
量は、０．１〜２０重量％（以下、単に％で示す。）、
特に０．１〜１０％が好ましい。医薬品として用いる場
合は、１〜２０％、特に１〜１０％が好ましい。また飲
食物として用いる場合は、０．１〜１０％、特に０．１
〜５％が好ましい。ツラノース、パラチノースまたはパ
ラチノース類縁体の１日の合計摂取量は、年齢、体重、
症状等に応じて異なるが、０．１〜１０ｇ、特に０．５
〜７ｇが好ましい。これらを１日に１回または数回に分
けて摂取することが好ましい。The compounding amount of turanose, palatinose or palatinose analog in the intestinal butyric acid bacteria growth promoter of the present invention is 0.1 to 20% by weight (hereinafter simply referred to as%),
In particular, 0.1 to 10% is preferable. When used as a pharmaceutical, 1 to 20%, particularly 1 to 10% is preferable. When used as food or drink, 0.1 to 10%, particularly 0.1%
~ 5% is preferred. Total daily intake of turanose, palatinose or palatinose analogs depends on age, weight,
It varies depending on the symptoms and the like, but is 0.1 to 10 g, particularly 0.5
~ 7 g is preferred. It is preferable to take these once or several times a day.
【００１２】本発明の腸内酪酸菌生育促進剤は、食中
毒、消化器疾患、日和見菌由来の下痢症及び便秘症等に
有効である。The intestinal butyric acid bacteria growth promoter of the present invention is effective for food poisoning, gastrointestinal diseases, diarrhea derived from opportunistic bacteria and constipation.
【００１３】[0013]
【００１４】参考例１ ロペラミドを５日間投与して人工的に便秘を誘発させた
ラット（ｎ＝５）の盲腸内容物中の低級脂肪酸（酢酸、
プロピオン酸及び酪酸）を定量した。なお対照としてロ
ペラミド未投与群を用いた。酢酸は、投与群が０．４０
４％（盲腸内容物１００ｇに対する生成％）、未投与群
は０．３７８％であり、プロピオン酸は、投与群が０．
２２４％、未投与群が０．１８４％であり、酪酸は、投
与群が０．１９７％、未投与群が０．２８６％であり、
酢酸及びプロビオン酸はロペラミド投与の有無による差
はあまりなかったが、酪酸量は便秘により有意に減少し
た（ｐ＝０．０８）。これから、腸内酪酸量は便秘によ
り低下し、酪酸の生成量を高めることが便秘改善に有効
であることが示唆された。Reference Example 1 Lower fatty acids (acetic acid, acetic acid, etc.) in the cecal contents of rats (n = 5) in which constipation was induced artificially by administering loperamide for 5 days
(Propionic acid and butyric acid). In addition, a loperamide non-administration group was used as a control. Acetic acid was 0.40 in the administration group.
4% (% production based on 100 g of cecal content), 0.378% in the non-administration group, and 0.3% in the administration group for propionic acid.
224%, the non-administration group was 0.184%, and butyric acid was 0.197% in the administration group, 0.286% in the non-administration group,
Acetic acid and propionic acid showed little difference depending on the presence or absence of loperamide administration, but butyric acid content was significantly reduced by constipation (p = 0.08). This suggests that the amount of butyric acid in the intestine decreases due to constipation, and that increasing the amount of butyric acid is effective in improving constipation.
【００１５】試験例１ 有用菌、有害菌及び日和見菌の
各種糖類の資化性試験 有用菌としてビフィドバクテリウム ロンガム（Bifido
bacterium longum）ＪＣＭ−１２１７株、ビフィドバク
テリウム ビフィダム（Bif. bifidum）ＪＣＭ−１２５
５株、ラクトバチルス アシドフィラス（Lactobacillu
s acidophilus）Ｌ−５４及びクロストリジウム ブチ
リカム ＪＣＭ−１３９１株、有害菌としてクロストリ
ジウム パーフリンゲンス ＪＣＭ−１２９０株、並び
に日和見菌としてバクテロイデス ブルガタス ＪＣＭ
−５８２６を用いた。表１及び２に示す各単糖類、少糖
類、多糖類及び糖アルコールを単独で０．５％含有する
ＰＹＦ（Ｐｅｐｔｏｎ Ｙｅａｓｔ ｅｘｔｒａｃｔ
Ｆｉｌｄｅｓ ｓｏｌｕｔｉｏｎ）培地に、菌数が１０
7 ｃ．ｆ．ｕとなるように、各菌を単独で接種した。こ
れらを３７℃で３日間、嫌気的に培養し、該培養液の濁
度（ＯＤ６００ｎｍ）及びpHを測定した。結果を表１に
示す。Test Example 1 Utilization test of various saccharides of useful bacteria, harmful bacteria and opportunistic bacteria As useful bacteria, Bifidobacterium longum (Bifido)
bacterium longum) JCM-1217 strain, Bifidobacterium bifidum (Bif. bifidum) JCM-125
Five strains of Lactobacillus acidophilus
s acidophilus) L-54 and Clostridium butyricum JCM-1391, Clostridium perfringens JCM-1290 as a harmful bacterium, and Bacteroides vulgartus JCM as an opportunistic bacterium
-5826 was used. PYF (Pepton Yeast extract) containing 0.5% of each monosaccharide, oligosaccharide, polysaccharide and sugar alcohol alone shown in Tables 1 and 2
Fields solution) medium contains 10 bacteria
7 c. f. Each bacterium was inoculated independently so as to obtain u. These were anaerobically cultured at 37 ° C. for 3 days, and the turbidity (OD 600 nm) and pH of the culture were measured. Table 1 shows the results.
【００１６】[0016]
【表１】 [Table 1]
【００１７】[0017]
【表２】 [Table 2]
【００１８】ツラノース、パラチノース及びパラチノー
ス類縁体であるパラチニット、１−Ｏ−α−Ｄ−グルコ
ピラノシル−Ｄ−マンニトール、６−Ｏ−α−Ｄ−グル
コピラノシル−Ｄ−グルシトールは、有害菌及び日和見
菌には全く資化されず、クロストリジウム ブチリカム
ＪＣＭ−１３９１株に高選択的に資化された。特にツ
ラノース、パラチノースは、ポジティブコントロールで
あるグルコースよりも高い資化性を示した。Turanose, palatinose and palatinit analogs such as palatinit, 1-O-α-D-glucopyranosyl-D-mannitol and 6-O-α-D-glucopyranosyl-D-glucitol are harmful bacteria and opportunistic bacteria. It was not assimilated at all and was highly selectively assimilated into Clostridium butyricum JCM-1391 strain. In particular, turanose and palatinose showed higher assimilation than glucose as a positive control.
【００１９】試験例２ 生成低級脂肪酸の定量 ツラノース、パラチノースまたはパラチノース類縁体を
単独で０．５％含むＰＹＦ培地にクロストリジウム ブ
チリカム ＪＣＭ−１３９１株を菌数が１０7c. f. uと
なるように接種し、３７℃で３日間嫌気的に培養した。
該培養液をフィルターで濾過後、高速液体クロマトグラ
フィーにより低級脂肪酸（乳酸、酢酸及び酪酸）を定量
した。濁度、pH、各低級脂肪酸生成量、その合計生成
量、及び該合計生成量に対する酪酸生成量を表３に示
す。なお対照としてグルコースを用いた。Test Example 2 Determination of Lower Fatty Acids Produced Clostridium butyricum JCM-1391 strain was inoculated to a PYF medium containing 0.5% of turanose, palatinose or a palatinose analog alone so that the number of bacteria would be 10 7 cfu. The cells were cultured anaerobically at 37 ° C. for 3 days.
After filtering the culture solution through a filter, lower fatty acids (lactic acid, acetic acid and butyric acid) were quantified by high performance liquid chromatography. Table 3 shows the turbidity, the pH, the amount of each lower fatty acid produced, the total amount produced, and the amount of butyric acid produced with respect to the total produced amount. Glucose was used as a control.
【００２０】[0020]
【表３】 [Table 3]
【００２１】ツラノース、パラチノース、６−Ｏ−α−
Ｄ−グルコピラノシル−Ｄ−グルシトールを用いると、
クロストリジウム ブチリカム ＪＣＭ−１３９１によ
り資化され、グルコースの場合と同等またはそれ以上の
酪酸が生成した。またツラノース、パラチノースを用い
ると、低級脂肪酸の合計生成量が多く、ツラノース、６
−Ｏ−α−Ｄ−グルコピラノシル−Ｄ−グルシトールを
用いると、低級脂肪酸合計生成量に対する酪酸生成量が
多かった。Turanose, palatinose, 6-O-α-
With D-glucopyranosyl-D-glucitol,
It was assimilated by Clostridium butyricum JCM-1391 and produced as much or more butyric acid as glucose. When turanose and palatinose are used, the total amount of lower fatty acids produced is large, and turanose, 6
When -O-α-D-glucopyranosyl-D-glucitol was used, the amount of butyric acid produced relative to the total amount of lower fatty acids produced was large.
【００２２】試験例３ 糞便培養試験法による各糖類の
低級脂肪酸の定量 ヒトの新鮮便を４０ｇとり、４倍重量のリン酸緩衝液
（pH６．０）に均一に懸濁後、３７℃で２４時間嫌気的
に前培養し、予め糞便中の栄養源を消費させた。次いで
表４に示すオリゴ糖または食物繊維をそれぞれ糞便懸濁
液と等量（終濃度０．５％）添加し、３７℃で２４時間
嫌気的に本培養した。培養液を濾過後、高速液体クロマ
トグラフィーにより、生成した低級脂肪酸（酢酸、プロ
ピオン酸及び酪酸）を定量した。尚、数値は糖液のかわ
りに水を用いたものをブランク値とし、各々ブランク値
をさしひいた値を示した。結果を表４に示す。Test Example 3 Determination of Lower Fatty Acids of Each Sugar by Stool Culture Test Method Take 40 g of human fresh stool, uniformly suspend it in a 4 times weight phosphate buffer (pH 6.0), and then suspend it at 37 ° C. for 24 hours. The culture was pre-cultured anaerobically for a period of time, and a nutrient source in feces was consumed in advance. Next, an oligosaccharide or a dietary fiber shown in Table 4 was added in the same amount as the fecal suspension (final concentration: 0.5%), and cultivated anaerobically at 37 ° C. for 24 hours. After filtering the culture solution, the produced lower fatty acids (acetic acid, propionic acid and butyric acid) were quantified by high performance liquid chromatography. In addition, the numerical value showed the value which used water instead of the sugar liquid as the blank value, and each blank value was subtracted. Table 4 shows the results.
【００２３】[0023]
【表４】 [Table 4]
【００２４】ツラノース、パラチノース１水和物には、
高い酪酸生成効果が認められた。これから、ツラノー
ス、パラチノースを用いれば、腸内細菌叢により効果的
に酪酸が生成されることが、間接的に立証された。Turanose and palatinose monohydrate include:
A high butyric acid producing effect was observed. From this, it was indirectly proved that the use of turanose and palatinose effectively produced butyric acid by the intestinal flora.
【００２５】実施例１及び２表５及び表６に示す配合で
飲料及び錠剤を常法に従い製造した。これらはいずれも
腸内酪酸菌の生育を促進するものであった。Examples 1 and 2 Beverages and tablets were prepared according to the conventional methods using the formulations shown in Tables 5 and 6. These all promoted the growth of intestinal butyric acid bacteria.
【００２６】[0026]
【表５】 パラチノース １ｇ ビタミンＣ ０．３ｇ 糖類（砂糖、果糖ぶどう糖液糖） １０ｇ 香料 ０．０２５ｇ 蒸留水 バランス 合計 １００ml[Table 5] Palatinose 1g Vitamin C 0.3g Sugars (sugar, fructose-glucose liquid sugar) 10g Flavor 0.025g Distilled water Balance 100ml
【００２７】[0027]
【表６】 パラチノース １０ｇ 賦形剤 ４０ｇ 香料 ０．１ｇ 滑沢剤 ２ｇ エリスリトール ４７．９ｇ 合計 １００ｇTable 6 Palatinose 10g Excipient 40g Flavor 0.1g Lubricant 2g Erythritol 47.9g Total 100g
【００２８】[0028]
【発明の効果】本発明の腸内酪酸菌生育促進剤を用いれ
ば、腸内の有害菌に利用されず、腸内の酪酸菌に高選択
的に資化されて酪酸菌の生育を促進し、酪酸生成量を増
加させることができる。According to the present invention, the use of the intestinal butyric acid bacteria growth promoter of the present invention is not utilized by intestinal harmful bacteria and is highly selectively utilized by intestinal butyric acid bacteria to promote the growth of butyric acid bacteria. , Butyrate production can be increased.
フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｋ 31/7016 Ａ６１Ｋ 31/70 ６０４ 35/74 35/74 Ｚ Ｃ１２Ｎ 1/20 Ｃ１２Ｎ 1/20 Ａ (Ｃ１２Ｎ 1/38 Ｃ１２Ｒ 1:145） (Ｃ１２Ｎ 1/20 Ｃ１２Ｒ 1:145） (72)発明者 本多 泰揮 栃木県芳賀郡市貝町赤羽2606 花王株式会 社研究所内 Ｆターム(参考） 4B018 MD29 ME11 4B065 AA23X BB16 BB34 CA41 CA44 4C086 AA01 AA02 EA01 MA01 MA04 NA14 ZA73 4C087 AA01 AA02 BC69 CA09 MA01 NA14 ZA73 Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat II (reference) A61K 31/7016 A61K 31/70 604 35/74 35/74 Z C12N 1/20 C12N 1/20 A (C12N 1/38 (C12R 1: 145) (C12N 1/20 C12R 1: 145) (72) Inventor Yasunori Honda 2606 Kabane-cho, Akagamachi, Haga-gun, Tochigi Prefecture F-term in Kao Corporation Research Laboratory 4B018 MD29 ME11 4B065 AA23X BB16 BB34 CA41 CA44 4C086 AA01 AA02 EA01 MA01 MA04 NA14 ZA73 4C087 AA01 AA02 BC69 CA09 MA01 NA14 ZA73
Claims (2)
ノース類縁体を有効成分とする腸内酪酸菌生育促進剤。An intestinal butyric acid bacteria growth promoter comprising turanose, palatinose or a palatinose analog as an active ingredient.
（Clostridium butyricum）属菌である請求項１記載の
腸内酪酸菌生育促進剤。2. The intestinal butyric acid bacteria growth promoter according to claim 1, wherein the butyric acid bacterium is a bacterium belonging to the genus Clostridium butyricum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31298098A JP3999894B2 (en) | 1998-11-04 | 1998-11-04 | Intestinal butyric acid bacteria growth promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31298098A JP3999894B2 (en) | 1998-11-04 | 1998-11-04 | Intestinal butyric acid bacteria growth promoter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000139451A true JP2000139451A (en) | 2000-05-23 |
| JP3999894B2 JP3999894B2 (en) | 2007-10-31 |
Family
ID=18035799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP31298098A Expired - Fee Related JP3999894B2 (en) | 1998-11-04 | 1998-11-04 | Intestinal butyric acid bacteria growth promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3999894B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004049093A (en) * | 2002-07-18 | 2004-02-19 | Meiji Milk Prod Co Ltd | Food composition and medicine for increasing intestinal butyric acid |
| WO2004067037A1 (en) * | 2003-01-30 | 2004-08-12 | Ajinomoto Co., Inc. | Intestinal environment controlling agent for oral use and normal intestinal flora growing kit for oral use |
| WO2007114378A1 (en) * | 2006-03-31 | 2007-10-11 | Nippon Paper Chemicals Co., Ltd. | Composition for beverage or food |
| WO2008120570A1 (en) * | 2007-03-19 | 2008-10-09 | National University Corporation Okayama University | Culture medium for production of protein or proliferation of virus |
| JP2020074695A (en) * | 2018-11-06 | 2020-05-21 | 株式会社明治 | Composition for promoting proliferation of genus coprococcus bacterium |
-
1998
- 1998-11-04 JP JP31298098A patent/JP3999894B2/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004049093A (en) * | 2002-07-18 | 2004-02-19 | Meiji Milk Prod Co Ltd | Food composition and medicine for increasing intestinal butyric acid |
| WO2004067037A1 (en) * | 2003-01-30 | 2004-08-12 | Ajinomoto Co., Inc. | Intestinal environment controlling agent for oral use and normal intestinal flora growing kit for oral use |
| WO2007114378A1 (en) * | 2006-03-31 | 2007-10-11 | Nippon Paper Chemicals Co., Ltd. | Composition for beverage or food |
| JPWO2007114378A1 (en) * | 2006-03-31 | 2009-08-20 | 日本製紙ケミカル株式会社 | Eating and drinking composition |
| CN101415342B (en) * | 2006-03-31 | 2013-07-17 | 日本制纸化学株式会社 | Composition for beverage or food |
| WO2008120570A1 (en) * | 2007-03-19 | 2008-10-09 | National University Corporation Okayama University | Culture medium for production of protein or proliferation of virus |
| JP2020074695A (en) * | 2018-11-06 | 2020-05-21 | 株式会社明治 | Composition for promoting proliferation of genus coprococcus bacterium |
| JP7216260B2 (en) | 2018-11-06 | 2023-02-01 | 株式会社明治 | Composition for promoting growth of Coprococcus spp. |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3999894B2 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zaporozhets et al. | The prebiotic potential of polysaccharides and extracts of seaweeds | |
| JP4455333B2 (en) | Probiotic bacteria: Lactobacillus fermentum | |
| JP4008974B2 (en) | Bifidobacterium growth promoting composition and use thereof | |
| KR102345546B1 (en) | Multi-fiber prebiotic formulation for digestive health, weight control, immune boosting and health improvement | |
| Al-Sheraji et al. | Fermentation and non-digestibility of Mangifera pajang fibrous pulp and its polysaccharides | |
| AU2005232497B2 (en) | Preventive and/or therapeutic agent for inflammatory bowel diseases | |
| JP2008504038A (en) | Pre-biological preparation | |
| KR20120031522A (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN109718255A (en) | The preparation method of enzyme powder is still drank after a night in a kind of elimination and the elimination containing the ingredient is still drank after a night and uses composition | |
| AU2019201637A1 (en) | Compositions Comprising a Mixture of Bacteria Comprising Pediococcus and Lactobacillus and Methods for Decreasing the Effects of Alcohols | |
| CN102811720A (en) | Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells | |
| Sauceda et al. | Impact of fruit dietary fibers and polyphenols on modulation of the human gut microbiota | |
| JP6261688B2 (en) | QOL improvement or persistence agent | |
| JP3999894B2 (en) | Intestinal butyric acid bacteria growth promoter | |
| JP2018145161A (en) | Composition for inhibiting elevation of blood pressure and method for producing the same | |
| KR20060083190A (en) | Use of fermentation liquor using microorganisms from bamboo | |
| JP3008138B2 (en) | Intestinal environment improving agent containing guar gum enzymatic degradation product as active ingredient | |
| Mitsou et al. | Impact of a jelly containing short-chain fructo-oligosaccharides and Sideritis euboea extract on human faecal microbiota | |
| JP2019097544A (en) | Novel bacteria belonging to bifidobacterium and compositions comprising the same | |
| Kuda et al. | Effects of dietary concentration of laminaran and depolymerised alginate on rat cecal microflora and plasma lipids | |
| JP2022518261A (en) | Yeast products for use as prebiotic agents and compositions containing them | |
| JP2876541B2 (en) | Bifidobacterium growth promoter | |
| JP5422201B2 (en) | Fermented wort and its use | |
| JP4201401B2 (en) | Intestinal bifidobacteria growth promoter | |
| KR100930251B1 (en) | Bifidobacterium longum having the ability of reducing cholesterol in blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041020 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20041020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070109 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070305 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070807 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070810 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110817 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110817 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120817 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120817 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |